Baseer Maroof, LCSW · Raleigh, NC · Adults 21+
What the evidence says
The short version: CBT with exposure has the strongest record. Here are the numbers behind it, and where medication fits.
In short
- CBT beats placebo for anxiety disorders: a moderate effect across 41 placebo-controlled trials.
- Exposure is the active ingredient for phobias, and a core part of CBT for panic and social anxiety.
- For GAD and panic, guidelines treat CBT and SSRIs as options; choose by preference. Benzodiazepines aren’t recommended for panic.
- Medication decisions are a conversation with your prescriber.
The numbers
Carpenter 2018; Mayo-Wilson 2014; Wolitzky-Taylor 2008; NICE CG113.
What “moderate” means
Carpenter’s meta-analysis compared CBT with placebo conditions (pill or psychological), not with no treatment. Beating a placebo by g = 0.56 is a solid result, and it held up for depression symptoms too (g = 0.31). (Carpenter 2018)
Guidelines
GAD (NICE CG113)
Stepped care. Start with education and self-help; then individual CBT or applied relaxation, or an SSRI. Neither has been shown to be better, so choose by preference. If medication: consider sertraline first.
Panic disorder (NICE CG113)
CBT, 7–14 hours total. Benzodiazepines shouldn’t be used, because long-term outcomes are worse. Antidepressants are the only medication it recommends for long-term use.
Social anxiety (NICE CG159)
Individual CBT built for social anxiety, based on the Clark and Wells or Heimberg models.
Specific phobia
Exposure-based treatment. See phobias.
Medication
Talk to your doctor
SSRIs can help, take weeks to work, and need a prescriber to start, adjust or stop. Tell them about everything else you take, including supplements and alcohol.
Benzodiazepines
They work fast and can feel like a rescue. In 2020 the FDA required a strengthened boxed warning about misuse, addiction, physical dependence and withdrawal, noting dependence can develop even when they’re taken as prescribed. Don’t stop one suddenly; taper with your prescriber. (FDA 2020)
Sources
All sources, linked6 references⌄
- Carpenter JK et al. (2018). Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials. Depression and Anxiety, 35(6), 502–514. pmc.ncbi.nlm.nih.gov/articles/PMC5992015/
- Mayo-Wilson E et al. (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry, 1(5), 368–376. pmc.ncbi.nlm.nih.gov/articles/PMC4287862/
- Wolitzky-Taylor KB et al. (2008). Psychological approaches in the treatment of specific phobias: a meta-analysis. Clinical Psychology Review, 28(6), 1021–1037. pubmed.ncbi.nlm.nih.gov/18410984/
- NICE (2011, updated 2020). Generalised anxiety disorder and panic disorder in adults: management (CG113). www.nice.org.uk/guidance/cg113/chapter/Recommendations
- NICE (2013). Social anxiety disorder: recognition, assessment and treatment (CG159). www.nice.org.uk/guidance/cg159/chapter/recommendations
- U.S. FDA (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class
Related on this site